Integrated Traditional Chinese and Western Medicine Center, Beijing You An Hospital, Capital Medical University, Beijing 100069, China.
General Department of Infectious Diseases, Beijing You An Hospital, Capital Medical University, Beijing 100069, China.
J Tradit Chin Med. 2020 Jun;40(3):467-472. doi: 10.19852/j.cnki.jtcm.2020.03.016.
To evaluate the effectiveness and safety of Jinhua Qinggan granules in the treatment of patients with novel coronavirus pneumonia (COVID-19).
Eighty cases of COVID-19 diagnosed from January 24 to February 17, 2020 in Beijing YouAn Hospital Affiliated to Capital Medical University were retrospectively analyzed. All 80 patients received symptomatic and supportive treatment. Among them, 44 patients took Jinhua Qinggan granules (treatment group) within 24 h of admission, and the remaining 36 patients either did not take Jinhua Qinggan granules or took the granules for less than 2 d (control group). In this study, we compared the duration of viral nucleic acid detection and of pneumonia absorption improvement between the two groups.
Among the 80 cases, 37 were male (46%) and 43 were female (54%) with age ranging from 15 to 86 years, with an average age of 51.19 years. The average duration of viral nucleic acid detection was (7 ± 4) d in the Jinhua Qinggan administration group and (10 ± 4) d for the control group (P = 0.010), following which, nucleic acid tests were negative. Of the two groups, 56.82% in the Jinhua Qinggan treatment group and 27.78% in the control group demonstrated negative nucleic acid tests within 7 d or less. The 7-day viral clearance rate was significantly higher in the Jinhua Qinggan group compared with the control group (P = 0.009). Furthermore, the pneumonia recovery time indicated by chest CT was (8 ± 4) d in the Jinhua Qinggan group, which was significantly shorter than the control group, at (10 ± 5) d (P = 0.021). No adverse reactions were found in the treatment group after taking this medicine.
In patients with COVID-19, Jinhua Qinggan granules can effectively shorten the duration of nucleic acid detection and promote the absorption of pneumonia inflammatory exudate without obvious adverse reactions.
评价金花清感颗粒治疗新型冠状病毒肺炎（COVID-19）患者的有效性和安全性。
回顾性分析 2020 年 1 月 24 日至 2 月 17 日首都医科大学附属北京佑安医院收治的 80 例 COVID-19 患者。所有 80 例患者均接受对症支持治疗。其中 44 例患者在入院 24 h 内服用金花清感颗粒（治疗组），其余 36 例患者未服用金花清感颗粒或服用时间不足 2 d（对照组）。本研究比较了两组患者病毒核酸检测转阴时间和肺炎吸收改善时间。
80 例患者中，男 37 例（46%），女 43 例（54%）；年龄 15~86 岁，平均年龄 51.19 岁。治疗组病毒核酸检测转阴时间为（7±4）d，对照组为（10±4）d，两组比较差异有统计学意义（P=0.010），之后核酸检测均为阴性。两组患者中，治疗组 56.82%在 7 d 内核酸检测转阴，对照组为 27.78%，差异有统计学意义（P=0.009）。治疗组 7 天病毒清除率明显高于对照组（P=0.009）。此外，治疗组胸部 CT 提示肺炎吸收时间为（8±4）d，明显短于对照组的（10±5）d，差异有统计学意义（P=0.021）。治疗组患者服药后未发现不良反应。
金花清感颗粒治疗 COVID-19 患者可有效缩短核酸检测转阴时间，促进肺炎渗出性炎症吸收，且无明显不良反应。
